China’s AI Manufacturing Boom Masks Weak Consumer Economy, Citi Says 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears 
Trump Says No Hormuz Strait Tolls During 60-Day Iran Ceasefire 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
US Dollar Hits One-Year High as Hawkish Fed Outlook Overshadows Middle East Developments 
Oil Prices Drop as U.S.-Iran Talks Ease Supply Concerns 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
France Faces Long Road to Economic Rebalancing as Weak Demand and High Rates Weigh, Says Citi 
Russia Stocks End Flat as MOEX Index Hits New 52-Week Low; Gold Falls and Oil Mixed 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Japan Keeps Markets Guessing as Yen Nears 40-Year Low, Raising Intervention Risks 
Japan Manufacturing Growth Accelerates in June as Orders Surge Despite Iran War Cost Pressures 
Moderna Inc. enters a historic $1 billion deal with China to research, develop, and produce exclusive mRNA medicines in the country. The agreement, announced amid growing Sino-American tensions, signifies Beijing's increasing openness to foreign pharmaceutical involvement.
The Cambridge, Massachusetts-based pharmaceutical and biotechnology company announced the new deal with Chinese officials on Wednesday, July 5. The agreement is for Moderna to research, develop and produce messenger RNA medicines in the country.
CNBC noted that an agreement was reached despite the growing tensions between China and the United States. Moderna and Beijing signed a memorandum of understanding (MOU) and land collaboration deal to develop drugs that will be made "exclusively for the Chinese people." This means the two sides agreed that the new drug would never be exported and remain in China.
A local media publication reported earlier this week that Moderna is set to invest about $1 billion in the project. It was added that Moderna's chief executive officer, Stephane Bancel, is set to visit Shanghai, possibly to talk more about the deal and for facility inspection.
"These agreements are focused on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China," the company's spokesman stated.
In a separate statement that was sent to Yahoo Finance, Moderna said, "We signed a memorandum of understanding and a related land collaboration agreement to work toward opportunities for Moderna to research, develop and manufacture mRNA medicines in China."
The deal shows that Moderna is trying to take advantage of the success of its COVID-19 vaccine that has been used on people worldwide. The vaccine used a platform called mRNA to push human cells to make an immune response against a virus. At any rate, the agreement was sealed on Wednesday, and this is Moderna's very first deal with the Chinese government.
Photo by: Ian Hutchinson/Unsplash
